AGP Picks
View all

The Middle East Health Journal
Provided by AGP

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

Press releases published on September 29, 2026

Solaris Endovascular Expands Leadership Team to Support Global Growth and Commercialization
Sep. 29, 2026

Solaris Endovascular Expands Leadership Team to Support Global Growth and Commercialization

Indeterminate EIN Presswire
BioPREVAIL and CEPI launch global Biosecurity Innovation Challenge to support 100 Days Mission
Sep. 29, 2026

BioPREVAIL and CEPI launch global Biosecurity Innovation Challenge to support 100 Days Mission

Indeterminate EIN Presswire
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Sep. 29, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Indeterminate GlobeNewswire
DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.
Sep. 29, 2026

DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.

Indeterminate GlobeNewswire
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Sep. 29, 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Indeterminate GlobeNewswire
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Sep. 29, 2026

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

Indeterminate GlobeNewswire
HL7 Launches Break the Code to Build the Next Generation of Healthcare Interoperability Talent
Sep. 29, 2026

HL7 Launches Break the Code to Build the Next Generation of Healthcare Interoperability Talent

Indeterminate GlobeNewswire
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
Sep. 29, 2026

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

Indeterminate GlobeNewswire
Pyxis Oncology Announces Proposed Public Offering
Sep. 29, 2026

Pyxis Oncology Announces Proposed Public Offering

Indeterminate GlobeNewswire
Vireo Growth Inc. Announces Put/Call Agreement in Connection with Loan Acquisition
Sep. 29, 2026

Vireo Growth Inc. Announces Put/Call Agreement in Connection with Loan Acquisition

Indeterminate GlobeNewswire
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Sep. 29, 2026

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Indeterminate GlobeNewswire
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep. 29, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Sep. 29, 2026

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Indeterminate GlobeNewswire
Equillium Announces Poster Presentations at the 7th International AHR Conference
Sep. 29, 2026

Equillium Announces Poster Presentations at the 7th International AHR Conference

Indeterminate GlobeNewswire
Acquisition of Own Shares
Sep. 29, 2026

Acquisition of Own Shares

Indeterminate GlobeNewswire
Inkoop van eigen aandelen
Sep. 29, 2026

Inkoop van eigen aandelen

Indeterminate GlobeNewswire
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Sep. 29, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep. 29, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Immunocine Names Janet Maendel, DO (EU), DNM, Director of Clinical Affairs
Sep. 29, 2026

Immunocine Names Janet Maendel, DO (EU), DNM, Director of Clinical Affairs

Indeterminate GlobeNewswire
New Jersey Communities to Mark Knock Out Opioid Abuse Day on October 6
Sep. 29, 2026

New Jersey Communities to Mark Knock Out Opioid Abuse Day on October 6

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Middle East Health Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.